Progressive Multiple Sclerosis Clinical Trial
— IPBio-SePOfficial title:
Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
Verified date | May 2018 |
Source | University Hospital, Clermont-Ferrand |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background: High dose biotin is a therapeutic option for French progressive Multiple
Sclerosis (MS) patients, without relapse for at least one year, since June 1, 2016. Despite
the inflammatory activity of progressive forms of MS is known to be low, several publications
mentioned clinical and/or radiological activity for biotin-treated patients.
Objectives:
1. To determine if high dose biotin increase the clinical inflammatory activity of patients
with a progressive form of MS.
2. To compare the clinical characteristics of the relapses that occurred with biotin or
not.
3. To describe the characteristics of the patients with a clinical inflammatory activity
with biotin.
Methods: This is a national, academic, observational and retrospective study comparing one
group of progressive MS patients with high dose biotin to another group without this
treatment using a propensity score, in intention to treat. The main judgment criterion is the
annualized relapse rate (ARR) from the beginning of the biotin to the last evaluation
available before the data extraction. A Student's t test will be used. A negative binomial
modelling with relapses counting over a period of exposure and taking into account the inter
and intra center variability will be used. The statistical tests will be adapted to the
nature of the variables concerning the secondary judgment criteria.
Expected results: This French national study will provide a better knowledge of the
inflammatory activity of the progressive forms of MS treated with high dose biotin. If an
increased clinical inflammatory activity is highlighted with biotin a prospective study will
be necessary to confirm the result before a specific information of the scientific community
and the patients about this risk or even an amendment of prescription rules in order to
secure the use of the product. On the contrary, the absence of increased risk of clinical
inflammatory activity with biotin would help to reassure the prescriber and the patient about
the innocuity of the treatment.
Status | Enrolling by invitation |
Enrollment | 3000 |
Est. completion date | April 30, 2019 |
Est. primary completion date | February 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - For the patients treated with biotin : - progressive form of MS (primary or secondary) - age between 18 and 80 years - Expanded Disability Status Scale (EDSS) between 3 and 7.5 at the beginning of biotin - treatment with biotin 300 mg per day at least one time, ongoing or stopped - no relapse in the year preceding biotin introduction - follow-up in an MS expert center - For the controls : - progressive form of MS (primary or secondary) - age between 18 and 80 years - Expanded Disability Status Scale (EDSS) between 3 and 7.5 at the baseline - EDMUS data base fulfilled at least three times during the two previous years - no relapse in the year preceding the baseline - follow-up in an MS expert center Exclusion Criteria: - For all participants : - other disease modifying therapy (DMT) than interferon, methotrexate, mycophenolate mofetil, azathioprine, rituximab, ocrelizumab - For the controls : - treatment with biotin actually or in the past - follow-up in an MS expert center who do not provide exhaustive information about biotin |
Country | Name | City | State |
---|---|---|---|
France | CHU Clermont-FERRAND | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | MedDay Pharmaceuticals SA, OFSEP (Observatoire Français de la Sclérose en Plaques), SFSEP (Société Francophone de la Sclérose en Plaques) |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relapses with biotin | To determine if high dose biotin increases the clinical inflammatory activity of patients with a progressive form of MS using the annualized relapse rate (ARR) comparing to a control group | at day 1 (through study completion, an average of 1 year) | |
Secondary | Clinical characteristics of the relapses with biotin | To compare the clinical characteristics of the relapses that occurred with biotin or not. | at day 1 (through study completion, an average of 1 year) | |
Secondary | Characteristics of patients with relapse with biotin | To describe the characteristics of the patients with a clinical inflammatory activity with biotin | at day 1 (through study completion, an average of 1 year) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02282826 -
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT02804594 -
A Study of Oxidative Pathways in MS Fatigue
|
Phase 2 | |
Completed |
NCT04120675 -
Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis
|
N/A | |
Completed |
NCT01719159 -
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05740722 -
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT03980145 -
G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis
|
N/A | |
Completed |
NCT03269071 -
Neural Stem Cell Transplantation in Multiple Sclerosis Patients
|
Phase 1 | |
Not yet recruiting |
NCT05811013 -
Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
|
N/A | |
Not yet recruiting |
NCT04289909 -
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
|
N/A | |
Recruiting |
NCT05685784 -
Multiple Sclerosis Prediction and Monitoring of Progression Study
|
N/A | |
Completed |
NCT03493841 -
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT03302806 -
Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
|
||
Recruiting |
NCT05441488 -
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT04695080 -
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06451159 -
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
|
Phase 1 | |
Completed |
NCT03423121 -
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT02580669 -
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
|
N/A | |
Enrolling by invitation |
NCT05706220 -
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
|
||
Recruiting |
NCT01815632 -
Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
|
Phase 2 | |
Recruiting |
NCT01364246 -
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
|
Phase 1/Phase 2 |